Michael F. Price and David Einhorn like Pfizer
| December 9th, 2010 | ||
| Two well regarded value-focused hedge fund gurus have commented this week on how they see investment opportunities in Pfizer Inc (NYSE: PFE). The pharmaceutical giant’s former CEO Jeffrey B. Kindler abruptly announced his “retirement” this past Sunday. Michael F. Price, who runs value-focused hedge fund MFP Investors LLC, mentioned today during an event that the stock is on his radar. Similarly, David Einhorn of Greenlight Capital told Reuters on Tuesday that he believed that the stock was substantially undervalued. As of 9/30/10, Einhorn’s Greenlight Capital and Price’s MFP Investors held 23,154,098 shares ($397mm) and 370,000 shares ($2.18mm) of Pfizer Inc, respectively. | ||
For Detailed Investor Profiles on these Investors, click below: |
Greenlight Capital |
Related People: Bruce Gutkin;
Related Entities: DME Advisors LP;
Related Article Tags: Multi-Strategy, Long Short, Equity, Debt and Global Macro Hedge Fund News; Hedge Fund Spotlight Reports
View Comments (1) | Add a Comment |
1 Comments
by jill on April 30th, 2012
I think investing in a drug company like this is such a great idea. They are making tons of money and the future looks so bright for them. Great choice here. écoles élémentaires d'Ottawa
More Recent Headlines
Kovner’s Caxton Associates opens Sydney office to lead push into Asia-Pacific |
Clarium Capital’s Patrick Wolff to launch Grand Master Capital Management |
Libre Max Capital’s Greg Lippmann continues to bet on subprime market |
Paulo Pellegrini discusses the market, bond prices and PSQR Capital’s future |
Corriente’s Mark Hart predicts China credit bubble will burst, launches Corriente China Opportunity Master Fund |
FrontPoint Partners’ investors get spooked by insider trading investigation, withdraw billions |
Santiago Rizzo preparing to launch TMT focused Outlier Capital hedge fund |
Exec Comp in Dodd-Frank: Institutional Investor Decisions and Regulatory Obligations |
The Great Ethanol Boondoggle |
How do you evaluate risk taking? |
